{"id":"NCT05136885","sponsor":"Merit E. Cudkowicz, MD","briefTitle":"HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose","officialTitle":"HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2022-02-21","primaryCompletion":"2023-08-25","completion":"2023-08-25","firstPosted":"2021-11-29","resultsPosted":"2024-08-28","lastUpdate":"2025-05-14"},"enrollment":161,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"SLS-005","otherNames":[]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"SLS-005","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.\n\nRegimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.","primaryOutcome":{"measure":"Disease Progression as Assessed by the ALSFRS-R Slope","timeFrame":"24 Weeks","effectByArm":[{"arm":"SLS-005","deltaMin":-0.91,"sd":0.09},{"arm":"Matching Placebo","deltaMin":-1.06,"sd":0.091}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40409314"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":120},"commonTop":["Fall","Muscular weakness","Fatigue","Neuromyopathy","Constipation"]}}